Emry Lloyd

News

FDA Approves Dostarlimab-gxly With Chemotherapy for Patients With Endometrial Cancer

08/16/2023

In July 2023, the FDA approved dostarlimab-gxly with carboplatin and paclitaxel for the treatment of advanced endometrial cancer in adult patients.

In July 2023, the FDA approved...

08/16/2023

Journal of Clinical Pathways

News

How Well Does the Enhancing Oncology Model Capture Treatment Costs in Disease Groups?

10/27/2023

Emry Lloyd ;

Katherine Baker, MD, and colleagues investigated how the Enhancing Oncology Model captures the performance risk and treatment costs within a disease.

Katherine Baker, MD, and...

10/27/2023

Journal of Clinical Pathways

News

Comparative Effectiveness for Bronchodilator Responsiveness Testing

02/09/2024

Emry Lloyd ;

A new study compares the efficacy of salbutamol administration via a nebulizer vs a metered-dose inhaler with a spacer for bronchodilator responsiveness testing.

A new study compares the...

02/09/2024

First Report Managed Care

News

Bayer AG Moves to Phase 2 Clinical Trial for New Gene Therapy for Parkinson Disease

01/24/2024

Emry Lloyd ;

Bayer AG receives approval to proceed with a phase 2 clinical trial for its gene therapy for patients with Parkinson disease.

Bayer AG receives approval to...

01/24/2024

Annals of Long-Term Care

Conference Coverage

Analysis Finds That Commuting Distance Affects Equitable Access to and Enrollment in US Cancer Clinical Trials

06/05/2023

Emry Lloyd ;

In an abstract presented at ASCO 2023, researchers found that one-way commuting distance to US-based cancer trial sites is a key barrier to socioeconomically equitable clinical trial enrollment.

In an abstract presented at ASCO...

06/05/2023

Journal of Clinical Pathways

News

Analysis of the Impact Bruton Tyrosine Kinase Inhibitor Discontinuation Has After First- or Second-Line Therapy

08/22/2023

Emry Lloyd ;

Researchers studied data on the outcomes of patients who received a BTKi in first or second line but subsequently discontinued treatment.

Researchers studied data on the...

08/22/2023

Journal of Clinical Pathways

News

The Influence of End-of-Life Care Costs on Episodic Value-Based Care Models

10/26/2023

Emry Lloyd ;

In this study, Gunjan Sharma, MS, and colleagues examine the impact of end-of-life costs on patients and caregivers, and how it influences value-based care models for physicians.

In this study, Gunjan Sharma,...

10/26/2023

Journal of Clinical Pathways

News

Patient-Reported Quality of Life in Patients With Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab

01/17/2024

Emry Lloyd ;

Researchers have found that a combination therapy of lenvatinib and pembrolizumab can have a statistically significant effect on health-related quality of life scores for patients with endometrial cancer.

Researchers have found that a...

01/17/2024

Journal of Clinical Pathways

News

Measurable Residual Disease as a Treatment Guide for Patients with Chronic Lymphocytic Leukemia

01/30/2024

Emry Lloyd ;

In a recent study, Talha Munir, PhD, and colleagues investigated whether personalization of ibrutinib and venetoclax treatment according to measurable residual disease has an impact on patients’ progression-free survival.

In a recent study, Talha Munir,...

01/30/2024

Journal of Clinical Pathways

Conference Coverage

Evaluation of a Medication Acquisition Program for Patient Access to Off-Label Treatment

06/21/2023

Emry Lloyd ;

Researchers analyzed the success of their institution’s medication acquisition program for patients with cancer, including tracking clinical benefit.

Researchers analyzed the success...

06/21/2023

Journal of Clinical Pathways